# Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/ > **Published:** 2026-06-19T12:43:51-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:51:32-04:00 > **Clinical Summary:** Learn about the synthetic cannabinoids schedule I placement including 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA by the DEA. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesSchedule_Istate_regulation4F-MDMB-BUTICA Clinical Summary The Drug Enforcement Administration has placed four [synthetic cannabinoids](https://cedclinic.com/synthetic-cannabinoid-parkinsons-trial-ser-252-funding/) (4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA) into Schedule I, classifying them as having no accepted medical use and high abuse potential. These designer cannabinoids, which are increasingly encountered in illicit drug markets and have been associated with severe adverse effects including psychosis, seizures, and cardiovascular complications, join dozens of other [synthetic cannabinoids](https://cedclinic.com/synthetic-cannabinoid-parkinsons-trial-ser-252-funding/) already scheduled by the DEA. This regulatory action reflects the persistent [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) challenge of synthetic cannabinoid analogs that evade existing drug laws through minor chemical modifications while maintaining or amplifying their potency and harm potential. Clinicians should be aware that patients presenting with acute psychiatric symptoms, neurological events, or cardiovascular emergencies may have used these novel substances, which are often sold as “K2” or “spice” and may not be disclosed by users due to stigma or lack of awareness. The practical takeaway for clinicians is to maintain vigilance for synthetic cannabinoid use in patients with unexplained severe adverse effects and to counsel patients that these unregulated substances carry unpredictable risks substantially greater than plant-derived cannabis. Clinical Perspective 💊 The DEA’s scheduling of these novel [synthetic cannabinoids](https://cedclinic.com/synthetic-cannabinoid-parkinsons-trial-ser-252-funding/) reflects the ongoing challenge of regulating emerging compounds faster than they are synthesized and distributed, a dynamic that complicates evidence-based [clinical decision-making](https://cedclinic.com/cannabinoids-mental-health-systematic-review-evidence-insights/). While Schedule I placement appropriately signals high abuse potential and lack of accepted medical use, clinicians should recognize that the proliferation of these designer compounds means patient exposure patterns may shift rapidly, making historical toxicity data less predictive of current harms. The clinical picture is further muddied by the fact that users often cannot reliably identify the specific cannabinoid content of products they consume, and adulterants or contaminants may contribute significantly to observed adverse effects. Providers encountering patients with acute psychiatric symptoms, [cannabinoid hyperemesis](https://cedclinic.com/cannabis-hyperemesis-syndrome-virginia-er-cases-surge/) syndrome, or cardiovascular complications should maintain a high index of suspicion for synthetic cannabinoid involvement even when standard urine drug screens are negative, and consider asking specifically about vaping products, herbal 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+4F-MDMB-BUTICA%2C+ADB-4en-PINACA%2C+5F-EDMB-PICA%2C+and+M...+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F01%2F2026-08517%2Fschedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F01%2F2026-08517%2Fschedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+4F-MDMB-BUTICA%2C+ADB-4en-PINACA%2C+5F-EDMB-PICA%2C+and+M...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F01%2F2026-08517%2Fschedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) - [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) - [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/dea-synthetic-dissociative-scheduling-diphenidine-schedule-i/) 📰 Source: [https://www.federalregister.gov/documents/2026/05/01/2026-08517/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and](https://www.federalregister.gov/documents/2026/05/01/2026-08517/schedules-of-controlled-substances-placement-of-4f-mdmb-butica-adb-4en-pinaca-5f-edmb-pica-and) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) Explore the DEA’s scheduling of CUMYL-PEGACLONE and its implications for [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) and regulation. [Read More](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) Review the temporary scheduling of 2-Fluorodeschloroketamine and its regulatory context. [Learn More](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/diphenidine-schedule-i-controlled-substance-update/) Understand the DEA’s decision to place Diphenidine in Schedule I and its clinical relevance. [Discover More](https://cedclinic.com/diphenidine-schedule-i-controlled-substance-update/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).